2024-517149-15-00RecruitingPhase 4
Systemic Neoadjuvant and adjuvant Control by Precision medicine in rectal cancer (SYNCOPE) – approach on high-risk group to reduce metastases
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Sept 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Applying a systemic control with precision approach over the course of the rectal cancer therapy is logistically feasible Applying a systemic control and precision approach as a treatment strategy, recurrence-free survival of rectal cancer patients is improved
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 11 Sept 2024
- Start date
- 1 Dec 2024
- Lead sponsor
- HUS-Yhtymae
- Diseases
- Colorectal cancer
- EU CT number
- 2024-517149-15-00
- EudraCT number
- 2020-003697-52
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1.) deficient MMR status, non-DPYD genotype 2) a contraindication to capecitabine, oxaliplatin or RT, 3) failing in blood tests that describe the adequate circulatory 4) liver and kidney function for chemotherapy
Who the study is looking for
- rectal adenocarcinoma, 2) WHO performance status 0-1, assessed by the MDT to be able to undergo CAPOX (capecitabine and oxaliplatin) treatment, 3) mrEMVI+ and 4) assessed by the MDT to require either RT or CRT by the current standards. In general, indications for clinical rectal carcinoma MDT to recommend RT or CRT are: T3-4 tumor at mid- or low rectum location, involvement of lymph nodes, threatened operative margin or mrEMVI
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| HUS-Yhtymae | Helsinki | Finland | Recruiting |
| Tampere University Hospital | Tampere | Finland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.